Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 15 Dec 2015 Status changed from not yet recruiting to recruiting as reported by University hospital Medical Information Network-Japan record.
- 15 Sep 2015 New trial record